


SARS-CoV-2 Ab Rapid Test

Easy-to-use blood test. Results within 15 minutes.

SARS-CoV-2 Ab Rapid Test is a device for qualitative detection of total antibodies against the 2019 novel coronavirus (SARS-CoV-2) in human serum, plasma or whole blood specimens.

COVID-19

The novel coronavirus SARS-CoV-2 is spreading rapidly worldwide. It is mainly transmitted via respiratory droplets and close contact. As a novel virus, there is no pre-existing immunity against it. In the vast majority of cases, the disease has a mild course, with slight to severe respiratory illness accompanied by other symptoms such as fever, cough and shortness of breath. In some cases, however, symptoms require urgent medical treatment and can lead to death. Elderly people and patients with comorbidities are particularly affected. It is important to identify infected people and determine the immune status of individuals in order to reduce the risk of spreading the virus and protect risk groups. An effective way to achieve this goal is immunochromatography, a simple and fast method to detect antibodies against the virus.



* Result pattern also in case patient is in a recurrent phase; ** Result pattern also in patients with past infections

Graphics for illustration purposes only

Currently, molecular tests are recommended by the WHO as front-line tests for the diagnosis of patients potentially infected with SARS-CoV-2. However, the use of this technology usually requires special equipment and infrastructure¹. Moreover, the nasopharyngeal swabs, used for molecular methods, are difficult to obtain and might pose a risk of infection during collection. Sampling for rapid tests is much easier, as only a small amount of blood is required. In the early phase of the disease, about 3 - 5 days² after the first symptoms appear, first IgM antibodies are detectable. IgG antibodies are formed after about 8 days² and indicate the start of convalescence and the presence of immunity to the virus.

Human

Diagnostics Worldwide

SARS-COV-2 Ab Rapid Test

Easy-to-use blood test. Results within 15 minutes.


Why testing for antibodies?

- > Aid in the diagnosis of symptomatic patients with suspected infection
- > Evaluation of immune response
- > Epidemiology, to determine the portion of the population infected but asymptomatic



Shutterstock photo ID: 1634579011

Three simple steps to the result



Add 10 μ l of specimen into the sample window.

Immediately add 2 drops of diluent buffer into the sample window.

Read the results after 15 minutes.

Technical information


SARS-CoV-2 Ab Rapid Test

REF: WJ-2750*

Colloidal gold-based immunochromatographic lateral flow device in cassette format for qualitative detection of total antibodies against SARS-CoV-2

- > Sample material: whole blood, serum or plasma
- > Kit size: 50 tests
- > Storage: 2...30°C
- > Clinically tested during the 2020 COVID-19 outbreak in China
- > CE marked IVD according to Directive 98/79/EC

Clinical performance depending on disease onset³



¹ <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>

² National Health Commission of the People's Republic of China, New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7)

³ Instruction for use VER: 20/02 (March 26, 2020)

* Manufactured by: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., No.31 Kexueyuan Road, Changping District, Beijing 102206, China
EC-REP: Qarad bv.b.a., Ciplastraat 3, B-2440 Geel, Belgium, Email: qarad@qarad.com



HUMAN Gesellschaft für Biochemica und Diagnostica mbH
Max-Planck-Ring 21 · 65205 Wiesbaden · Germany
Tel. +49 6122-9988-0 · Fax +49 6122-9988-100 · e-mail: human@human.de · www.human.de

Human

Diagnostics Worldwide


COVID-19 IgM-IgG Rapid Test

Easy-to-use blood test. Results within 15 minutes.

IgM-IgG combined antibody test for COVID-19 to qualitatively detect and differentiate IgM and IgG antibodies against the novel coronavirus SARS-CoV-2 in human serum, plasma or whole blood specimens in vitro.

COVID-19

The novel coronavirus SARS-CoV-2 is spreading rapidly worldwide. It is mainly transmitted via respiratory droplets and close contact. As a novel virus, there is no pre-existing immunity against it. In the vast majority of cases, the disease has a mild course, with slight to severe respiratory illness accompanied by other symptoms such as fever, cough and shortness of breath. In some cases, however, symptoms require urgent medical treatment and can lead to death. Elderly people and patients with comorbidities are particularly affected. It is important to identify infected people and determine the immune status of individuals in order to reduce the risk of spreading the virus and protect risk groups. An effective way to achieve this goal is immunochromatography, a simple and fast method to detect antibodies against the virus. The combined detection and differentiation of IgM and IgG antibodies allows providing information about the stage of the infection.



¹ Result pattern also in case patient is in a recurrent phase; ² Result pattern also in patients with past infections

Graphics for illustration purposes only

Currently, molecular tests are recommended by the WHO as front-line tests for the diagnosis of patients potentially infected with SARS-CoV-2. However, the use of this technology usually requires special equipment and infrastructure¹. Moreover, the nasopharyngeal swabs, used for molecular methods, are difficult to obtain and might pose a risk of infection during collection. Sampling for rapid tests is much easier, as only a small amount of blood is required. In the early phase of the disease, about 3-5 days² after the first symptoms appear, first IgM antibodies are detectable. IgG antibodies are formed after about 8 days² and indicate the start of convalescence and the presence of immunity to the virus.

Human

Diagnostics Worldwide

COVID-19 IgM-IgG Rapid Test

Easy-to-use blood test. Results within 15 minutes.


Why testing for IgM and IgG?

- > Aid in diagnosis of symptomatic patients with suspected infection
- > Evaluation of immune status
 - IgM => early phase of infection
 - IgM / IgG => active phase of infection
 - IgG => later phase or previous infection
- > Epidemiology, to determine the portion of the population infected but asymptomatic



Shutterstock photo ID: 1634579011

Three simple steps to the result



Add 10 µl (serum, plasma) or 20 µl (whole blood) into the sample window.

Immediately add 2-3 drops of diluent buffer into the sample window.

Read the results after 15 minutes.

Technical information

COVID-19 IgM-IgG Rapid Test

REF: 51-002-20*

Colloidal gold-based immunochromatographic lateral flow device in cassette format for qualitative detection of IgG and IgM antibodies against SARS-CoV-2

- > Sample material: whole blood, serum or plasma
- > Kit size: 20 tests
- > Results in 15 minutes
- > Storage: 18...26°C
- > Clinically validated through COVID-19 outbreak in China³
- > CE marked IVD according to Directive 98/79/EC



¹ <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>

² National Health Commission of the People's Republic of China, New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7)

³ Li Z. et al. 2020 Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis; <https://doi.org/10.1002/jmv.25727>

* Manufactured by: BioMedomics, Inc., 1100 Perimeter Park Dr., Ste. 104, Morrisville, NC 27560, USA
EC-REP: MT Promedt Consulting GmbH, Altenhofstrasse 80, 66386 St. Ingbert, Germany, +49-68-94-58 10 20

